

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT SELECTION RESULTS OF NATIONAL CENTRALIZED MEDICINES PROCUREMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group’s products Doxofylline Injection and Ambroxol Hydrochloride Injection, both in form of polypropylene ampoule, were selected in the tender for National Centralized Medicines Procurement (全國藥品集中採購) in the PRC on 3 February 2021. The Group’s Doxofylline Injection and Ambroxol Hydrochloride Injection passed the Consistency Evaluation of the Quality and Efficacy of Generic Drugs in January 2020 and December 2020 respectively, with details being set out in the announcements of the Company dated 6 February 2020 and 30 December 2020 respectively.

According to the tendering arrangement of National Centralized Medicines Procurement, the Group’s Doxofylline Injection will be exclusively supplied to 6 provinces/municipality including Hubei, Yunnan, Chongqing, Heilongjiang, Inner Mongolia and Ningxia, and Ambroxol Hydrochloride Injection will be exclusively supplied to 3 provinces/municipality including Shanghai, Tianjin and Qinghai. The Board expects that the tender results will be beneficial to rapid market development, formation of large-scale sales and increase in market share of the relevant new products, and will bring a positive result on the Group’s sales in the future.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Company Secretary

Hong Kong, 3 February 2021

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.